Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan

References

• McInnes I, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219.
   PubMed Web of Science ®Google Scholar
• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–1322.
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun. 2010;35:10–14.
   PubMed Web of Science ®Google Scholar
• Yu KH, See LC, Kuo CF, et al. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res. 2013;65:244–250.
   PubMed Web of Science ®Google Scholar
• Lai CH, Lai MS, Lai KL, et al. Nationwide population-based epidemiologic study of rheumatoid arthritis in Taiwan. Clin Exp Rheumatol. 2012;30:358–363.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Luo SF, See LC, et al. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int. 2013;33:355–360.
   PubMed Web of Science ®Google Scholar
• Chiu YM, Lai MS, Lin HY, et al. Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. Clin Exp Rheumatol. 2014;32:898–903.
   PubMedGoogle Scholar
• Chang J, Lang H. The economic cost of rheumatoid arthritis in Taiwan [Abstract]. Value Health. 2014;17:A773.
   PubMedGoogle Scholar
• Wang BCM, Tang CH, Furnback W, et al. Disease burden of rheumatoid arthritis in Taiwan: a population-based analysis [Abstract]. Value Health. 2014;17:A45.
   Web of Science ®Google Scholar
• Panés J, Chan G, Maller E, et al. Effects of oral tofacitinib on patient-reported outcomes in patients with moderate to severe Crohn's disease: results of two Phase 2B randomized placebo-controlled trials [Abstract]. Gastroenterology. 2016;150(S1):S1003.
   Google Scholar
• Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis. 2015;18:685–713.
   PubMed Web of Science ®Google Scholar
• Liao TL, Lin CH, Chen YM, et al. Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan. PLoS One. 2016;11:e0153217.
   PubMed Web of Science ®Google Scholar
• Campbell J, Lowe D, Sleeman MA. Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. Br J Pharmacol. 2011;162:1470–1484.
   PubMed Web of Science ®Google Scholar
• Pope J, Combe B. Unmet needs in the treatment of rheumatoid arthritis. OJRA. 2013;3:65–78.
   Google Scholar
• Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–629.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970–981.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895–1905.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kim HY, Lee SH, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis. 2014;73:124–131.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150–1158.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised Phase 3 trial. Lancet. 2013;381:451–460.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253–261.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–468.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Lee EB, Curtis JR,et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89.
   PubMed Web of Science ®Google Scholar
• Lee MY, Park SK, Park SY, et al. Cost-effectiveness of tofacitinib in the treatment of moderate to severe rheumatoid arthritis in South Korea. Clin Ther. 2015;37:1662–1676.
   PubMed Web of Science ®Google Scholar
• Claxton L, Jenks M, Taylor M, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States. J Manag Care Spec Pharm. 2016;22:1088–1102.
   PubMedGoogle Scholar
• Claxton L, Taylor M, Gerber RA, et al. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Curr Med Res Opin. 2018;34:1991–2000.
   PubMed Web of Science ®Google Scholar
• Claxton L, Taylor M, Moynagh D, et al. Modeling the costs and outcomes associated with sequence of treatment with and without tofacitinib for the treatment of moderate to severe rheumatoid arthritis in the US [Abstract]. Ann Rheum Dis. 2015;74:319–320.
   Google Scholar
• Claxton L, Taylor M, Soonasra A, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis after methotrexate or after 1 or 2 TNF inhibitors from a U.S. payer perspective. J Manag Care Spec Pharm. 2018;24:1010–1017.
   PubMed Web of Science ®Google Scholar
• Woolcott JC, Blackhouse G, Claxton L, et al. The economic value of tofacitinib 5 mg BID in the treatment of moderate to severe rheumatoid arthritis: a Canadian analysis [Abstract]. Ann Rheum Dis. 2015;74:785.
   Google Scholar
• Taiwan Center for Drug Evaluation. Health Technology Assessment cost-benefit analysis methodology guidelines. 2013 [cited 2019 Mar 4]. Available from: http://nihta.cde.org.tw/ReadFile/?p=SRule&n=5c4de492-3c50-4349-940c-d494f0cecc87.pdf
   Google Scholar
• Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 2015 [cited 2019 Feb 18]. Available from: http://www.cdc.gov/nchs/icd/icd9cm.htm
   Google Scholar
• NHIRD. National Health Insurance Research Database Data Files. 2015 [cited 2016 Oct 22]. Available from: http://nhird.nhri.org.tw/en/Data_Subsets.html#S4
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324.
   PubMed Web of Science ®Google Scholar
• Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford). 2010;49:1197–1199.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422–437.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681.
   PubMed Web of Science ®Google Scholar
• Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol. 2004;31:1098–1102.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284–288.
   PubMed Web of Science ®Google Scholar
• Bergrath E, Gerber RA, Gruben D, et al. Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis. Int J Rheumatol. 2017;2017:8417249.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–1411.
   PubMed Web of Science ®Google Scholar
• Wollenhaupt J, Silverfield J, Lee EB, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months [Abstract]. Arthritis Rheum. 2011;63:S152–S153.
   Google Scholar
• Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop. 2014;5:504–511.
   PubMedGoogle Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–494.
   PubMed Web of Science ®Google Scholar
• Oppong R, Kaambwa B, Nuttall J, et al. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. Eur J Health Econ. 2013;14:197–209.
   PubMed Web of Science ®Google Scholar
• Taiwan Chapter of International Society for Pharmacoeconomics and Outcomes Research (TaSPOR). Guidelines of methodological standards for pharmacoeconomic evaluation. Version 1.0 ed. Taipei, Taiwan; 2006.
   Google Scholar
• NHIA. National Health Insurance Administration. 2016 [cited 2017 Nov 4]. Available from: http://www.nhi.gov.tw/Query/query1.aspx?menu=20&menu_id=712&WD_ID=831
   Google Scholar
• Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15:576–585.
   PubMedGoogle Scholar
• Kuo H-L, Cherh HK, Hua WC. Health care utilization associated with adverse events among RA patients treated by TNF-alpha in Taiwan [Abstract]. Mod Rheumatol. 2016;26:S50. (ICW-C3-2).
   Google Scholar
• Lang HC, Chen HW, Chiou TJ, et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016;19:923–927.
   PubMed Web of Science ®Google Scholar
• Bansback N, Ara R, Karnon J, et al. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. Pharmacoeconomics. 2008;26:395–408.
   PubMed Web of Science ®Google Scholar
• Souto A, Maneiro JR, Gómez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55:523–534.
   PubMed Web of Science ®Google Scholar